Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,786
archived clinical trials in
Dermatology

Efficacy and Safety Study of Mepolizumab in Subjects With Moderate to Severe Atopic Dermatitis
Study 205050: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Mepolizumab Administered Subcutaneously in Subjects With Moderate to Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Surrey,
Efficacy and Safety Study of Mepolizumab in Subjects With Moderate to Severe Atopic Dermatitis
Study 205050: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Mepolizumab Administered Subcutaneously in Subjects With Moderate to Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Surrey,
Click here to add this to my saved trials
Efficacy and Safety Study of Mepolizumab in Subjects With Moderate to Severe Atopic Dermatitis
Study 205050: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Mepolizumab Administered Subcutaneously in Subjects With Moderate to Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Indianapolis, IN
Efficacy and Safety Study of Mepolizumab in Subjects With Moderate to Severe Atopic Dermatitis
Study 205050: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Mepolizumab Administered Subcutaneously in Subjects With Moderate to Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Efficacy and Safety Study of Mepolizumab in Subjects With Moderate to Severe Atopic Dermatitis
Study 205050: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Mepolizumab Administered Subcutaneously in Subjects With Moderate to Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
San Antonio, TX
Efficacy and Safety Study of Mepolizumab in Subjects With Moderate to Severe Atopic Dermatitis
Study 205050: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Mepolizumab Administered Subcutaneously in Subjects With Moderate to Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
San Antonio, TX
Click here to add this to my saved trials
Efficacy and Safety Study of Mepolizumab in Subjects With Moderate to Severe Atopic Dermatitis
Study 205050: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Mepolizumab Administered Subcutaneously in Subjects With Moderate to Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Norfolk, VA
Efficacy and Safety Study of Mepolizumab in Subjects With Moderate to Severe Atopic Dermatitis
Study 205050: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Mepolizumab Administered Subcutaneously in Subjects With Moderate to Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Norfolk, VA
Click here to add this to my saved trials
Efficacy and Safety Study of Mepolizumab in Subjects With Moderate to Severe Atopic Dermatitis
Study 205050: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Mepolizumab Administered Subcutaneously in Subjects With Moderate to Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
New Albany, IN
Efficacy and Safety Study of Mepolizumab in Subjects With Moderate to Severe Atopic Dermatitis
Study 205050: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Mepolizumab Administered Subcutaneously in Subjects With Moderate to Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
New Albany, IN
Click here to add this to my saved trials
Efficacy and Safety Study of Mepolizumab in Subjects With Moderate to Severe Atopic Dermatitis
Study 205050: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Mepolizumab Administered Subcutaneously in Subjects With Moderate to Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Chicago, IL
Efficacy and Safety Study of Mepolizumab in Subjects With Moderate to Severe Atopic Dermatitis
Study 205050: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Mepolizumab Administered Subcutaneously in Subjects With Moderate to Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Chicago, IL
Click here to add this to my saved trials
Efficacy and Safety Study of Mepolizumab in Subjects With Moderate to Severe Atopic Dermatitis
Study 205050: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Mepolizumab Administered Subcutaneously in Subjects With Moderate to Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
New York, NY
Efficacy and Safety Study of Mepolizumab in Subjects With Moderate to Severe Atopic Dermatitis
Study 205050: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Mepolizumab Administered Subcutaneously in Subjects With Moderate to Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
New York, NY
Click here to add this to my saved trials
Efficacy and Safety Study of Mepolizumab in Subjects With Moderate to Severe Atopic Dermatitis
Study 205050: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Mepolizumab Administered Subcutaneously in Subjects With Moderate to Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Fort Smith, AR
Efficacy and Safety Study of Mepolizumab in Subjects With Moderate to Severe Atopic Dermatitis
Study 205050: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Mepolizumab Administered Subcutaneously in Subjects With Moderate to Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Fort Smith, AR
Click here to add this to my saved trials
Efficacy and Safety Study of Mepolizumab in Subjects With Moderate to Severe Atopic Dermatitis
Study 205050: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Mepolizumab Administered Subcutaneously in Subjects With Moderate to Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Pittsburgh, PA
Efficacy and Safety Study of Mepolizumab in Subjects With Moderate to Severe Atopic Dermatitis
Study 205050: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Mepolizumab Administered Subcutaneously in Subjects With Moderate to Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Efficacy and Safety Study of Mepolizumab in Subjects With Moderate to Severe Atopic Dermatitis
Study 205050: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Mepolizumab Administered Subcutaneously in Subjects With Moderate to Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Hurst, TX
Efficacy and Safety Study of Mepolizumab in Subjects With Moderate to Severe Atopic Dermatitis
Study 205050: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Mepolizumab Administered Subcutaneously in Subjects With Moderate to Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Hurst, TX
Click here to add this to my saved trials
Evaluating Treatment Resistant Dermatitis TaroIIR
Study to Evaluate Resistant Disease/Max Adherence to Topical Treatments in Patients With Atopic Dermatitis and Psoriasis
Status: Enrolling
Updated:  12/31/1969
Wake Forest University Health Sciences, Department of Dermatology
mi
from
Winston-Salem, NC
Evaluating Treatment Resistant Dermatitis TaroIIR
Study to Evaluate Resistant Disease/Max Adherence to Topical Treatments in Patients With Atopic Dermatitis and Psoriasis
Status: Enrolling
Updated: 12/31/1969
Wake Forest University Health Sciences, Department of Dermatology
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-blind Extension Period And A Cross-over Open Label Extension Period
Status: Enrolling
Updated:  12/31/1969
Southern California Dermatology, Inc.
mi
from
Santa Ana, CA
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-blind Extension Period And A Cross-over Open Label Extension Period
Status: Enrolling
Updated: 12/31/1969
Southern California Dermatology, Inc.
mi
from
Santa Ana, CA
Click here to add this to my saved trials
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-blind Extension Period And A Cross-over Open Label Extension Period
Status: Enrolling
Updated:  12/31/1969
Clinical Science Institute
mi
from
Santa Monica, CA
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-blind Extension Period And A Cross-over Open Label Extension Period
Status: Enrolling
Updated: 12/31/1969
Clinical Science Institute
mi
from
Santa Monica, CA
Click here to add this to my saved trials
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-blind Extension Period And A Cross-over Open Label Extension Period
Status: Enrolling
Updated:  12/31/1969
Yale New Haven Hospital - Radiology
mi
from
New Haven, CT
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-blind Extension Period And A Cross-over Open Label Extension Period
Status: Enrolling
Updated: 12/31/1969
Yale New Haven Hospital - Radiology
mi
from
New Haven, CT
Click here to add this to my saved trials
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-blind Extension Period And A Cross-over Open Label Extension Period
Status: Enrolling
Updated:  12/31/1969
Yale School of Medicine
mi
from
New Haven, CT
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-blind Extension Period And A Cross-over Open Label Extension Period
Status: Enrolling
Updated: 12/31/1969
Yale School of Medicine
mi
from
New Haven, CT
Click here to add this to my saved trials
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-blind Extension Period And A Cross-over Open Label Extension Period
Status: Enrolling
Updated:  12/31/1969
Investigational Drug Services
mi
from
New Haven, CT
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-blind Extension Period And A Cross-over Open Label Extension Period
Status: Enrolling
Updated: 12/31/1969
Investigational Drug Services
mi
from
New Haven, CT
Click here to add this to my saved trials
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-blind Extension Period And A Cross-over Open Label Extension Period
Status: Enrolling
Updated:  12/31/1969
Church Street Research Unit
mi
from
New Haven, CT
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-blind Extension Period And A Cross-over Open Label Extension Period
Status: Enrolling
Updated: 12/31/1969
Church Street Research Unit
mi
from
New Haven, CT
Click here to add this to my saved trials
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-blind Extension Period And A Cross-over Open Label Extension Period
Status: Enrolling
Updated:  12/31/1969
Park Avenue Dermatology
mi
from
Orange Park, FL
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-blind Extension Period And A Cross-over Open Label Extension Period
Status: Enrolling
Updated: 12/31/1969
Park Avenue Dermatology
mi
from
Orange Park, FL
Click here to add this to my saved trials
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-blind Extension Period And A Cross-over Open Label Extension Period
Status: Enrolling
Updated:  12/31/1969
Olympian Clinical Research
mi
from
Tampa, FL
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-blind Extension Period And A Cross-over Open Label Extension Period
Status: Enrolling
Updated: 12/31/1969
Olympian Clinical Research
mi
from
Tampa, FL
Click here to add this to my saved trials
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-blind Extension Period And A Cross-over Open Label Extension Period
Status: Enrolling
Updated:  12/31/1969
Rose Radiology
mi
from
Tampa, FL
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-blind Extension Period And A Cross-over Open Label Extension Period
Status: Enrolling
Updated: 12/31/1969
Rose Radiology
mi
from
Tampa, FL
Click here to add this to my saved trials
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-blind Extension Period And A Cross-over Open Label Extension Period
Status: Enrolling
Updated:  12/31/1969
Forward Clinical Trials
mi
from
Tampa, FL
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-blind Extension Period And A Cross-over Open Label Extension Period
Status: Enrolling
Updated: 12/31/1969
Forward Clinical Trials
mi
from
Tampa, FL
Click here to add this to my saved trials
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-blind Extension Period And A Cross-over Open Label Extension Period
Status: Enrolling
Updated:  12/31/1969
MedaPhase, Inc.
mi
from
Newnan, GA
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-blind Extension Period And A Cross-over Open Label Extension Period
Status: Enrolling
Updated: 12/31/1969
MedaPhase, Inc.
mi
from
Newnan, GA
Click here to add this to my saved trials
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-blind Extension Period And A Cross-over Open Label Extension Period
Status: Enrolling
Updated:  12/31/1969
Dawes Fretzin Clinical Research Group, LLC
mi
from
Indianapolis, IN
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-blind Extension Period And A Cross-over Open Label Extension Period
Status: Enrolling
Updated: 12/31/1969
Dawes Fretzin Clinical Research Group, LLC
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-blind Extension Period And A Cross-over Open Label Extension Period
Status: Enrolling
Updated:  12/31/1969
Dawes Fretzin Dermatology Group
mi
from
Indianapolis, IN
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-blind Extension Period And A Cross-over Open Label Extension Period
Status: Enrolling
Updated: 12/31/1969
Dawes Fretzin Dermatology Group
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-blind Extension Period And A Cross-over Open Label Extension Period
Status: Enrolling
Updated:  12/31/1969
Vital Prospects Clinical Research Institute, P.C.
mi
from
Tulsa, OK
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-blind Extension Period And A Cross-over Open Label Extension Period
Status: Enrolling
Updated: 12/31/1969
Vital Prospects Clinical Research Institute, P.C.
mi
from
Tulsa, OK
Click here to add this to my saved trials
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-blind Extension Period And A Cross-over Open Label Extension Period
Status: Enrolling
Updated:  12/31/1969
Health Concepts
mi
from
Rapid City, SD
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-blind Extension Period And A Cross-over Open Label Extension Period
Status: Enrolling
Updated: 12/31/1969
Health Concepts
mi
from
Rapid City, SD
Click here to add this to my saved trials
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-blind Extension Period And A Cross-over Open Label Extension Period
Status: Enrolling
Updated:  12/31/1969
Virginia Clinical Research, Inc.
mi
from
Norfolk, VA
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-blind Extension Period And A Cross-over Open Label Extension Period
Status: Enrolling
Updated: 12/31/1969
Virginia Clinical Research, Inc.
mi
from
Norfolk, VA
Click here to add this to my saved trials
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-blind Extension Period And A Cross-over Open Label Extension Period
Status: Enrolling
Updated:  12/31/1969
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-blind Extension Period And A Cross-over Open Label Extension Period
Status: Enrolling
Updated: 12/31/1969
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Click here to add this to my saved trials
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-blind Extension Period And A Cross-over Open Label Extension Period
Status: Enrolling
Updated:  12/31/1969
Park Avenue Dermatology Administrative Annex
mi
from
Orange Park, FL
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-blind Extension Period And A Cross-over Open Label Extension Period
Status: Enrolling
Updated: 12/31/1969
Park Avenue Dermatology Administrative Annex
mi
from
Orange Park, FL
Click here to add this to my saved trials
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-blind Extension Period And A Cross-over Open Label Extension Period
Status: Enrolling
Updated:  12/31/1969
NorthShore University HealthSystem Dermatology Clinical Trials Unit
mi
from
Skokie, IL
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-blind Extension Period And A Cross-over Open Label Extension Period
Status: Enrolling
Updated: 12/31/1969
NorthShore University HealthSystem Dermatology Clinical Trials Unit
mi
from
Skokie, IL
Click here to add this to my saved trials
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-blind Extension Period And A Cross-over Open Label Extension Period
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital - Clinical Unit for Research Trials in Skin (CURTIS)
mi
from
Boston, MA
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-blind Extension Period And A Cross-over Open Label Extension Period
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital - Clinical Unit for Research Trials in Skin (CURTIS)
mi
from
Boston, MA
Click here to add this to my saved trials
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-blind Extension Period And A Cross-over Open Label Extension Period
Status: Enrolling
Updated:  12/31/1969
Rockefeller University Hospital
mi
from
New York, NY
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-blind Extension Period And A Cross-over Open Label Extension Period
Status: Enrolling
Updated: 12/31/1969
Rockefeller University Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-blind Extension Period And A Cross-over Open Label Extension Period
Status: Enrolling
Updated:  12/31/1969
St George Dermatology and Skin Cancer Centre
mi
from
Kogarah,
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-blind Extension Period And A Cross-over Open Label Extension Period
Status: Enrolling
Updated: 12/31/1969
St George Dermatology and Skin Cancer Centre
mi
from
Kogarah,
Click here to add this to my saved trials
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-blind Extension Period And A Cross-over Open Label Extension Period
Status: Enrolling
Updated:  12/31/1969
University of Colorado Hospital Clinical and Translational Research Center, Inpatient Unit
mi
from
Aurora, CO
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-blind Extension Period And A Cross-over Open Label Extension Period
Status: Enrolling
Updated: 12/31/1969
University of Colorado Hospital Clinical and Translational Research Center, Inpatient Unit
mi
from
Aurora, CO
Click here to add this to my saved trials
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-blind Extension Period And A Cross-over Open Label Extension Period
Status: Enrolling
Updated:  12/31/1969
University of Colorado Hospital Clinical and Translational Research Center, Outpatient Clinic
mi
from
Aurora, CO
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-blind Extension Period And A Cross-over Open Label Extension Period
Status: Enrolling
Updated: 12/31/1969
University of Colorado Hospital Clinical and Translational Research Center, Outpatient Clinic
mi
from
Aurora, CO
Click here to add this to my saved trials
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-blind Extension Period And A Cross-over Open Label Extension Period
Status: Enrolling
Updated:  12/31/1969
University of Colorado Hospital, Anschutz Cancer Pavilion
mi
from
Aurora, CO
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-blind Extension Period And A Cross-over Open Label Extension Period
Status: Enrolling
Updated: 12/31/1969
University of Colorado Hospital, Anschutz Cancer Pavilion
mi
from
Aurora, CO
Click here to add this to my saved trials
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-blind Extension Period And A Cross-over Open Label Extension Period
Status: Enrolling
Updated:  12/31/1969
Tufts Medical Center
mi
from
Boston, MA
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-blind Extension Period And A Cross-over Open Label Extension Period
Status: Enrolling
Updated: 12/31/1969
Tufts Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-blind Extension Period And A Cross-over Open Label Extension Period
Status: Enrolling
Updated:  12/31/1969
Mount Sinai Department of Otolaryngology
mi
from
New York, NY
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-blind Extension Period And A Cross-over Open Label Extension Period
Status: Enrolling
Updated: 12/31/1969
Mount Sinai Department of Otolaryngology
mi
from
New York, NY
Click here to add this to my saved trials
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-blind Extension Period And A Cross-over Open Label Extension Period
Status: Enrolling
Updated:  12/31/1969
Investigational Drug Service
mi
from
Rochester, NY
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-blind Extension Period And A Cross-over Open Label Extension Period
Status: Enrolling
Updated: 12/31/1969
Investigational Drug Service
mi
from
Rochester, NY
Click here to add this to my saved trials
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-blind Extension Period And A Cross-over Open Label Extension Period
Status: Enrolling
Updated:  12/31/1969
Univ of Rochester Medical Center
mi
from
Rochester, NY
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-blind Extension Period And A Cross-over Open Label Extension Period
Status: Enrolling
Updated: 12/31/1969
Univ of Rochester Medical Center
mi
from
Rochester, NY
Click here to add this to my saved trials
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-blind Extension Period And A Cross-over Open Label Extension Period
Status: Enrolling
Updated:  12/31/1969
University of Utah MidValley Dermatology
mi
from
Murray, UT
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-blind Extension Period And A Cross-over Open Label Extension Period
Status: Enrolling
Updated: 12/31/1969
University of Utah MidValley Dermatology
mi
from
Murray, UT
Click here to add this to my saved trials
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-blind Extension Period And A Cross-over Open Label Extension Period
Status: Enrolling
Updated:  12/31/1969
University of Utah Medical Center
mi
from
Salt Lake City, UT
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-blind Extension Period And A Cross-over Open Label Extension Period
Status: Enrolling
Updated: 12/31/1969
University of Utah Medical Center
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-blind Extension Period And A Cross-over Open Label Extension Period
Status: Enrolling
Updated:  12/31/1969
Yale Hearing and Balance Center
mi
from
New Haven, CT
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-blind Extension Period And A Cross-over Open Label Extension Period
Status: Enrolling
Updated: 12/31/1969
Yale Hearing and Balance Center
mi
from
New Haven, CT
Click here to add this to my saved trials
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-blind Extension Period And A Cross-over Open Label Extension Period
Status: Enrolling
Updated:  12/31/1969
Tower Saint John's Imaging
mi
from
Santa Monica, CA
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-blind Extension Period And A Cross-over Open Label Extension Period
Status: Enrolling
Updated: 12/31/1969
Tower Saint John's Imaging
mi
from
Santa Monica, CA
Click here to add this to my saved trials
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-blind Extension Period And A Cross-over Open Label Extension Period
Status: Enrolling
Updated:  12/31/1969
Office of F. Monte Purcelli, MD
mi
from
Santa Monica, CA
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-blind Extension Period And A Cross-over Open Label Extension Period
Status: Enrolling
Updated: 12/31/1969
Office of F. Monte Purcelli, MD
mi
from
Santa Monica, CA
Click here to add this to my saved trials
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-blind Extension Period And A Cross-over Open Label Extension Period
Status: Enrolling
Updated:  12/31/1969
Edward B. Kampsen, MD
mi
from
Tampa, FL
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-blind Extension Period And A Cross-over Open Label Extension Period
Status: Enrolling
Updated: 12/31/1969
Edward B. Kampsen, MD
mi
from
Tampa, FL
Click here to add this to my saved trials
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-blind Extension Period And A Cross-over Open Label Extension Period
Status: Enrolling
Updated:  12/31/1969
University of Alabama at Birmingham, Dermatology at the Whitaker Clinic
mi
from
Birmingham, AL
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-blind Extension Period And A Cross-over Open Label Extension Period
Status: Enrolling
Updated: 12/31/1969
University of Alabama at Birmingham, Dermatology at the Whitaker Clinic
mi
from
Birmingham, AL
Click here to add this to my saved trials
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-blind Extension Period And A Cross-over Open Label Extension Period
Status: Enrolling
Updated:  12/31/1969
University of Alabama at Birmingham, The Kirklin Clinic
mi
from
Birmingham, AL
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-blind Extension Period And A Cross-over Open Label Extension Period
Status: Enrolling
Updated: 12/31/1969
University of Alabama at Birmingham, The Kirklin Clinic
mi
from
Birmingham, AL
Click here to add this to my saved trials
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-blind Extension Period And A Cross-over Open Label Extension Period
Status: Enrolling
Updated:  12/31/1969
Weill Cornell Medicine
mi
from
New York, NY
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-blind Extension Period And A Cross-over Open Label Extension Period
Status: Enrolling
Updated: 12/31/1969
Weill Cornell Medicine
mi
from
New York, NY
Click here to add this to my saved trials
A Phase 3 Study to Evaluate the Efficacy and Safety of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts
A Phase 3, Randomized, Double-Blind, Vehicle-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Mobile, AL
A Phase 3 Study to Evaluate the Efficacy and Safety of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts
A Phase 3, Randomized, Double-Blind, Vehicle-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Mobile, AL
Click here to add this to my saved trials